Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference TranscriptSeeking Alpha • 11/17/25
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/14/25
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 11/12/25
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 11/11/25
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression TranscriptSeeking Alpha • 11/07/25
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal StudyBenzinga • 11/07/25
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual MeetingGlobeNewsWire • 11/06/25
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation ConferenceGlobeNewsWire • 11/05/25
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual MeetingGlobeNewsWire • 10/17/25
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation AssociationGlobeNewsWire • 09/24/25
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025GlobeNewsWire • 08/29/25
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial ResultsGlobeNewsWire • 08/14/25
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationGlobeNewsWire • 08/06/25
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025GlobeNewsWire • 07/30/25
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025GlobeNewsWire • 07/17/25
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial ResultsGlobeNewsWire • 05/14/25
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance SheetSeeking Alpha • 05/03/25
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial ResultsGlobeNewsWire • 03/20/25
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare ConferenceGlobeNewsWire • 03/04/25
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a HumanGlobeNewsWire • 02/07/25
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewsWire • 01/29/25
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management BusinessSeeking Alpha • 01/28/25